Targeting aberrant enhancer landscapes in pancreatic cancer
靶向胰腺癌中的异常增强子景观
基本信息
- 批准号:10661753
- 负责人:
- 金额:$ 40.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-02 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:BindingBiological AssayCRISPR screenCellsCessation of lifeChromatinChromatin Remodeling FactorCollectionComplementComplexDependenceDevelopmentDiagnosisDiseaseDisseminated Malignant NeoplasmDuctal Epithelial CellElementsEmbryoEndodermEnhancersEpigenetic ProcessEventExperimental GeneticsFutureGene Expression ProfileGenesGenetic Enhancer ElementGenetic TranscriptionGenomeGenomic approachGenomicsGoalsHTATIP geneHumanInterventionKnock-outLeadLocationMaintenanceMalignant neoplasm of pancreasMapsMetastatic AdenocarcinomaMolecularMutationNeoplasm MetastasisOrganoidsPancreatic Ductal AdenocarcinomaPatientsPatternPhenotypePolycombPrimitive foregut structureProcessPrognosisRecurrenceResearchRoleSamplingSiteSourceSquamous CellSystemTestingTransplantationTumor PromotionUp-Regulationcancer celleffective therapyepigenetic therapyexperimental studyfunctional genomicsgain of functionin vivoinnovationinnovative technologiesinterestloss of functionneoplasticnovelpancreatic cancer cellspancreatic cancer patientspancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelprogenitorprogramsrestrainttargeted treatmenttherapeutic targettraittranscription factortranscriptometumor progression
项目摘要
Project Summary/Abstract
The central goal of this project is to develop strategies to epigenetically reprogram pancreatic cancer cells to
diminish metastatic spread. This objective is based on our recent demonstration that pancreatic cancer
metastasis is accompanied by a stereotypical pattern of enhancer activation. We implicated the pioneer
transcription factor FOXA1 as a driver of enhancer reprogramming and of metastatic spread in this context. In
this proposal, we seek to define the enhancer-metastasis connection. In doing so, we seek to nominate a new
class of epigenetic targets, which might be uniquely capable of eliminating metastatic potential. In the first Aim
of this proposal, we will employ a functional genomics approach to perturb every FOXA1-regulated gene and
enhancer and determine whether FOXA1-dependent metastasis can be suppressed. This approach will take
advantage of our recent innovations in domain-focused CRISPR screening and will deepen our understanding
of the pro-metastatic components of this epigenetic program. In the second Aim of this proposal, we will
investigate the earliest steps of the enhancer reprogramming process that occur prior to FOXA1 upregulation.
This effort builds from our unexpected observation that metastasis-specific enhancers are already present in
an accessible chromatin state in pre-metastatic pancreatic tumor cells. This suggests that additional molecular
events occur prior to FOXA1 upregulation to set the stage for enhancer reprogramming during metastasis. We
will investigate the transcription factor FOXA2, which our experiments suggest is the critical bookmark that
opens up metastasis-specific enhancers in pre-metastatic cancer cells. In addition, we will determine how
repressive Polycomb complexes act to restrain enhancer activation prior to FOXA1 upregulation. By evaluating
the consequences of FOXA2/Polycomb perturbation, we will provide a proof-of-concept that metastasis-
associated enhancers can be effaced at early stages of pancreatic cancer progression. The final Aim of this
proposal will be to extend our enhancer mapping studies into the squamous-subtype of pancreatic cancer,
which is a recently defined disease entity associated with a particularly dismal prognosis. We will employ a
newly characterized complement of patient-derived pancreatic cancer organoids to compare enhancer profiles
of squamous-subtype versus the more classical form of this disease. We will identify master-regulators of this
squamous transcriptional program, and perform genetic experiments to determine the role of such factors in
promoting tumor progression and metastatic spread. We will also determine whether squamous cell identity in
PDA is associated with unique epigenetic dependencies. Collectively, the proposed research will provide a
mechanistic framework for developing epigenetic therapies that target the unique enhancer configuration of
metastatic pancreatic cancer cells.
项目概要/摘要
该项目的中心目标是制定策略,对胰腺癌细胞进行表观遗传重编程,使其
减少转移扩散。这一目标是基于我们最近的证明,即胰腺癌
转移伴随着增强子激活的典型模式。我们牵连了先锋
转录因子 FOXA1 作为增强子重编程和转移扩散的驱动因素。在
在这个提案中,我们寻求定义增强子与转移的联系。在此过程中,我们寻求提名新的
一类表观遗传靶点,可能具有独特的消除转移潜力的能力。在第一个目标中
根据该提案,我们将采用功能基因组学方法来干扰每个 FOXA1 调节的基因,
增强子并确定是否可以抑制 FOXA1 依赖性转移。这种方法将采取
利用我们最近在以领域为中心的 CRISPR 筛选方面的创新,并将加深我们的理解
该表观遗传程序的促转移成分。在本提案的第二个目标中,我们将
研究 FOXA1 上调之前发生的增强子重编程过程的最早步骤。
这项工作建立在我们意想不到的观察基础上,即转移特异性增强子已经存在于
转移前胰腺肿瘤细胞中可接近的染色质状态。这表明额外的分子
事件发生在 FOXA1 上调之前,为转移过程中增强子重编程奠定基础。我们
将研究转录因子 FOXA2,我们的实验表明它是关键的书签
在转移前的癌细胞中打开转移特异性增强子。此外,我们将确定如何
抑制性 Polycomb 复合物在 FOXA1 上调之前抑制增强子激活。通过评估
FOXA2/Polycomb 扰动的后果,我们将提供转移的概念验证-
相关的增强子可以在胰腺癌进展的早期阶段被消除。本次活动的最终目的
建议将我们的增强子图谱研究扩展到胰腺癌的鳞状亚型,
这是最近定义的一种与特别糟糕的预后相关的疾病实体。我们将聘请一名
新鉴定的患者来源的胰腺癌类器官的补充物,用于比较增强子谱
鳞状亚型与该疾病的更经典形式的比较。我们将确定这个的主监管者
鳞状转录程序,并进行基因实验以确定这些因素在
促进肿瘤进展和转移扩散。我们还将确定鳞状细胞身份是否在
PDA 与独特的表观遗传依赖性相关。总的来说,拟议的研究将提供
开发针对独特增强子配置的表观遗传疗法的机制框架
转移性胰腺癌细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER VAKOC其他文献
CHRISTOPHER VAKOC的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER VAKOC', 18)}}的其他基金
Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia
阐明 SCP4 通路作为急性髓系白血病的多催化信号传导依赖性
- 批准号:
10753227 - 财政年份:2023
- 资助金额:
$ 40.48万 - 项目类别:
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer
在小细胞肺癌簇细胞变体中利用 POU2F3 成瘾
- 批准号:
10221648 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer
在小细胞肺癌簇细胞变体中利用 POU2F3 成瘾
- 批准号:
9980811 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
Targeting aberrant enhancer landscapes in pancreatic cancer
靶向胰腺癌中的异常增强子景观
- 批准号:
10199961 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer
在小细胞肺癌簇细胞变体中利用 POU2F3 成瘾
- 批准号:
10693821 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
Targeting aberrant enhancer landscapes in pancreatic cancer
靶向胰腺癌中的异常增强子景观
- 批准号:
9816984 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
Elucidating the function of PAX3-FOXO1 in rhabdomyosarcoma with molecular reporters and next-generation genome editing
利用分子报告基因和下一代基因组编辑阐明 PAX3-FOXO1 在横纹肌肉瘤中的功能
- 批准号:
10064134 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
Targeting aberrant enhancer landscapes in pancreatic cancer
靶向胰腺癌中的异常增强子景观
- 批准号:
10436243 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer
在小细胞肺癌簇细胞变体中利用 POU2F3 成瘾
- 批准号:
10450100 - 财政年份:2019
- 资助金额:
$ 40.48万 - 项目类别:
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia
BET 溴结构域抑制作为急性髓系白血病的靶向治疗
- 批准号:
10306382 - 财政年份:2013
- 资助金额:
$ 40.48万 - 项目类别:
相似国自然基金
基于Bacillus subtilis 细胞传感器介导的肠道环境中结直肠癌相关生物标志物的动态检测策略
- 批准号:82372355
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
CRISPR传感技术对稻田微生物甲基汞关键基因的检测机制研究
- 批准号:42377456
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
一种用于生物呼吸标记物检测的中红外全固态超短脉冲激光器的研究
- 批准号:62305188
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于微流控芯片的赤潮微藻及其生物毒素同步快速定量检测研究
- 批准号:42307568
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于镍纳米粒子催化新型生物传感器研制及应用于中药残留检测
- 批准号:82360857
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Epstein-Barr Virus nuclear antigen leader protein in transcription regulation
Epstein-Barr病毒核抗原前导蛋白在转录调控中的作用
- 批准号:
10829620 - 财政年份:2023
- 资助金额:
$ 40.48万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 40.48万 - 项目类别: